AllianceRx Walgreens Pharmacy Selected as Exclusive Distributor of VIVJOA®

Access to 240+ limited distribution drugs is available through Walgreens specialty pharmacy.

DEERFIELD, Ill., March 14, 2024 – Walgreens specialty pharmacy patients now have exclusive access to VIVJOA®, through AllianceRx Walgreens Pharmacy, a subsidiary of Walgreens.

VIVJOA (oteseconazole), manufactured by Mycovia Pharmaceuticals, Inc., is the first FDA-approved medication to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in post-menopausal women or women who are not of reproductive potential. 

The addition of this medication brings Walgreens enterprise specialty’s number of exclusive limited distribution drugs to among the highest of specialty pharmacies in the U.S.

“Having Mycovia select us as the exclusive specialty pharmacy partner of VIVJOA is a testament to the thorough care and oversight of this medication provided by Walgreens specialty pharmacists,” says Tracey James, RPh, chief operating officer, Walgreens specialty enterprise. “It’s not only how we care for the patients, but winning exclusive access to a limited distribution drug is also about how we support providers by getting their patients on therapy faster.”

In addition to VIVJOA, the following limited distribution drugs are available at AllianceRx Walgreens Pharmacy and select community-based specialty pharmacies.

  • Augtyro™ (repotrectinib), manufactured by Bristol Myers Squibb, is an oral prescription medicine used to treat non-small cell lung cancer (NSCLC) in adults that has spread within your chest or to other parts of the body, and is caused by an abnormal ROS1 gene.
  • Eylea® HD (aflibercept) Injection, manufactured by Regeneron, is approved to treat patients with neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
  • Entyvio® SQ (vedolizumab), manufactured by Takeda, is prescribed as maintenance therapy for adult patients with moderately to severely active ulcerative colitis after induction therapy with ENTYVIO intravenous.
  • Hemady® (dexamethasone), distributed by Edenbridge Pharmaceuticals, is the first and only 20 mg tablet of dexamethasone indicated for use with other anti-myeloma products for the treatment of adults with multiple myeloma.

For full prescribing information on these drugs, visit their manufacturer’s websites or

About Walgreens

Walgreens ( is included in the U.S. Retail Pharmacy and U.S. Healthcare segments of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy, and retail leader with a 170-year heritage of caring for communities. WBA’s purpose is to create more joyful lives through better health. Operating nearly 9,000 retail locations across America, Puerto Rico and the U.S. Virgin Islands, Walgreens is proud to be a neighborhood health destination serving nearly 10 million customers each day. Walgreens pharmacists play a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for the nation’s underserved populations. To best meet the needs of customers and patients, Walgreens offers a true omnichannel experience, with fully integrated physical and digital platforms supported by the latest technology to deliver high-quality products and services in communities nationwide.

Media Contact

Adrienne Foley, APR

Explore Themes in this Press Release